Harvard Bioscience, Inc. (HBIO)
Stock Price Chart
Key Info
| Market Cap | 128.51M |
| Revenue (ttm) | 105.47M |
| Net Income (ttm) | -8.17M |
| Shares Out | 38.94M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | 27.25 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 29, 2020 |
| Last Price | $3.30 |
| Previous Close | $3.21 |
| Change ($) | 0.09 |
| Change (%) | 2.80% |
| Day's Open | 3.19 |
| Day's Range | 3.15 - 3.31 |
| Day's Volume | 116,417 |
| 52-Week Range | 1.39 - 4.41 |
More Stats
| Market Cap | 128.51M |
| Enterprise Value | 179.75M |
| Earnings Date (est) | Nov 5, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 38.94M |
| Float | 34.37M |
| EPS (basic) | -0.21 |
| EPS (diluted) | -0.21 |
| FCF / Share | 0.24 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 7.24% |
| Payout Ratio | n/a |
| Shares Short | 1.36M |
| Short Ratio | 11.63 |
| Short % of Float | 3.95% |
| Beta | 1.52 |
| PE Ratio | n/a |
| Forward PE | 27.25 |
| P/FCF Ratio | 13.81 |
| PS Ratio | 1.22 |
| PB Ratio | 1.54 |
| Revenue | 105.47M |
| Operating Income | -2.45M |
| Net Income | -8.17M |
| Free Cash Flow | 9.31M |
| Net Cash | -51.24M |
| Net Cash / Share | -1.32 |
| Gross Margin | 61.21% |
| Operating Margin | -2.32% |
| Profit Margin | -7.70% |
| FCF Margin | 8.82% |
| ROA | -0.67% |
| ROE | -10.44% |
| ROIC | -2.90% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 116 | 121 | 77.41 | 105 | 109 | 109 | 105 | 111 | 109 | 108 |
| Revenue Growth | -3.81% | 56.02% | -25.94% | -3.81% | 0% | 3.32% | -5.4% | 2.12% | 0.63% | - |
| Gross Profit | 64.32 | 63.18 | 39.17 | 48.42 | 48.72 | 49.34 | 47.70 | 52.34 | 50.19 | 51.81 |
| Operating Income | 0.38 | 0.98 | -0.64 | -3.00 | -1.71 | 6.62 | 1.54 | 7.83 | 8.41 | 10.22 |
| Net Income | -4.69 | -2.92 | -0.87 | -4.31 | -19.04 | 2.36 | -1.83 | 2.37 | 3.81 | 19.02 |
| Shares Outstanding | 37.81 | 36.45 | 34.75 | 34.21 | 33.59 | 32.17 | 30.38 | 28.80 | 28.45 | 28.97 |
| Earnings Per Share | -0.12 | -0.08 | -0.02 | -0.13 | -0.57 | 0.07 | -0.06 | 0.08 | 0.13 | 0.65 |
| EPS Growth | - | - | - | - | - | - | - | -38.46% | -80% | - |
| Operating Cash Flow | 8.05 | 2.88 | 1.06 | 5.38 | 0.71 | 4.35 | 4.06 | 8.06 | 6.65 | 12.29 |
| Capital Expenditures | -1.22 | -0.99 | -0.88 | -1.45 | -2.95 | -0.86 | -1.56 | -1.74 | -1.48 | -0.81 |
| Free Cash Flow | 6.83 | 1.90 | 0.18 | 3.94 | -2.25 | 3.49 | 2.50 | 6.33 | 5.17 | 11.48 |
| Cash & Equivalents | 8.34 | 8.17 | 5.19 | 5.60 | 6.74 | 14.13 | 25.77 | 20.68 | 17.92 | 19.70 |
| Total Debt | 64.47 | 60.80 | 11.75 | 13.75 | 18.73 | 21.45 | 24.75 | 12.95 | 16.30 | 18.01 |
| Net Cash / Debt | -56.13 | -52.62 | -6.56 | -8.15 | -11.99 | -7.32 | 1.02 | 7.73 | 1.62 | 1.70 |
| Assets | 165 | 169 | 109 | 108 | 120 | 136 | 135 | 133 | 127 | 125 |
| Liabilities | 83.18 | 85.89 | 28.45 | 35.57 | 42.45 | 40.45 | 40.98 | 29.27 | 31.14 | 34.55 |
| Book Value | 81.69 | 82.72 | 80.90 | 72.20 | 77.60 | 95.47 | 94.49 | 104 | 95.50 | 90.25 |
Company Profile
Company Details
| Full Name | Harvard Bioscience, Inc. |
| Country | United States |
| Employees | 505 |
| CEO | James W. Green |
Stock Information
| Ticker Symbol | HBIO |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NASDAQ: HBIO |
| IPO Date | December 7, 2000 |
Description
Harvard Bioscience develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, and BTX brands. It also develops and manufactures data acquisition systems for use with custom amplifier configurations under; vivo-systems solution for in vivo recordings with microelectrode arrays; and vitro-systems for extracellular recordings from microelectrode arrays in vitro. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions under the DSI and Buxco brands. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists at pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.